RESUMEN
The present guideline is an update and extension of the ESPEN scientific guideline on Clinical Nutrition in Inflammatory Bowel Disease published first in 2017. The guideline has been rearranged according to the ESPEN practical guideline on Clinical Nutrition in Inflammatory Bowel Disease published in 2020. All recommendations have been checked and, if needed, revised based on new literature, before they underwent the ESPEN consensus procedure. Moreover, a new chapter on microbiota modulation as a new option in IBD treatment has been added. The number of recommendations has been increased to 71 recommendations in the guideline update. The guideline is aimed at professionals working in clinical practice, either in hospitals or in outpatient medicine, and treating patients with IBD. General aspects of care in patients with IBD, and speciï¬c aspects during active disease and in remission are addressed. All recommendations are equipped with evidence grades, consensus rates, short commentaries and links to cited literature.
Asunto(s)
Enfermedades Inflamatorias del Intestino , Terapia Nutricional , Humanos , Enfermedades Inflamatorias del Intestino/terapiaRESUMEN
BACKGROUND: This practical guideline is based on the ESPEN Guidelines on Chronic Intestinal Failure in Adults. METHODOLOGY: ESPEN guidelines have been shortened and transformed into flow charts for easier use in clinical practice. The practical guideline is dedicated to all professionals including physicians, dieticians, nutritionists, and nurses working with patients with chronic intestinal failure. RESULTS: This practical guideline consists of 112 recommendations with short commentaries for the management and treatment of benign chronic intestinal failure, including home parenteral nutrition and its complications, intestinal rehabilitation, and intestinal transplantation. CONCLUSION: This practical guideline gives guidance to health care providers involved in the management of patients with chronic intestinal failure.
Asunto(s)
Gastroenterología/normas , Insuficiencia Intestinal/terapia , Terapia Nutricional/normas , Adulto , Enfermedad Crónica , Femenino , Humanos , Masculino , Nutrición Parenteral en el Domicilio/normasRESUMEN
Obesity and the corresponding burden of related diseases is a major public health issue worldwide that is reaching pandemic proportions. Bariatric surgery is the only intervention that has been shown to result in substantial and lasting weight loss, and a decrease in overall mortality for patients with severe obesity. Consequently, the population of patients having undergone this procedure is increasing. Multifactorial weight-dependent and independent mechanisms underlying metabolic diseases could also drive preventable, but potentially life-threatening, long-term nutritional complications. However, given post-bariatric patients are prone to functional gastrointestinal symptoms and substantial weight loss, nutritional complications might be challenging. This Review is focused on the prevention and treatment of nutritional complications after bariatric surgery in the clinical setting.
Asunto(s)
Cirugía Bariátrica/efectos adversos , Desnutrición/epidemiología , Enfermedades Metabólicas/prevención & control , Obesidad Mórbida/cirugía , Cirugía Bariátrica/métodos , Femenino , Enfermedades Gastrointestinales/etiología , Humanos , Desnutrición/etiología , Desnutrición/fisiopatología , Obesidad Mórbida/complicaciones , Obesidad Mórbida/epidemiología , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/fisiopatología , Pérdida de PesoRESUMEN
This document is a summary of the French intergroup guidelines regarding the nutrition and physical activity (PA) management in digestive oncology. This collaborative work was produced under the auspices of all French medical and surgical societies involved in digestive oncology, nutrition and supportive care. It is based on published guidelines, recent literature review and expert opinions. Recommendations are graded according to the level of evidence. Malnutrition affects more than half of patients with digestive cancers and is often underdiagnosed. It has multiple negative consequences on survival, quality of life and risk of treatment complications. Consequently, in addition to anticancer treatments, supportive care including nutritional support and PA plays a central role in the management of digestive cancers. It is crucial to detect malnutrition (diagnostic criteria updated in 2019) early, to prevent it and to act against it at all stages of the cancer and at all times of the care pathway. In this context, we proposed recommendations for the evaluation and management in nutrition and PA in digestive oncology for each stage of the disease (perioperative setting, during radiation therapy, during systemic treatments, at the palliative phase, after cancer). Guidelines for nutrition and PA management aim at increasing awareness about malnutrition in oncology. They are continuously evolving and need to be regularly updated.
Asunto(s)
Calidad de Vida , Sociedades Médicas , Endopeptidasas , Ejercicio Físico , Estudios de Seguimiento , HumanosRESUMEN
BACKGROUND & AIMS: Intestinal failure (IF) is defined as "the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth". Functionally, it may be classified as type I acute intestinal failure (AIF), type II prolonged AIF and type III chronic intestinal failure (CIF) The ESPEN Workshop on IF was held in Bologna, Italy, on 15-16 October 2017 and the aims of this document were to highlight the current state of the art and future directions for research in IF. METHODS: This paper represents the opinion of experts in the field, based on current evidence. It is not a formal review, but encompasses the current evidence, with emphasis on epidemiology, classification, diagnosis and management. RESULTS: IF is the rarest form of organ failure and can result from a variety of conditions that affect gastrointestinal anatomy and function adversely. Assessment, diagnosis, and short and long-term management involves a multidisciplinary team with diverse expertise in the field that aims to reduce complications, increase life expectancy and improve quality of life in patients. CONCLUSIONS: Both AIF and CIF are relatively rare conditions and most of the published work presents evidence from small, single-centre studies. Much remains to be investigated to improve the diagnosis and management of IF and future studies should rely on multidisciplinary, multicentre and multinational collaborations that gather data from large cohorts of patients. Emphasis should also be placed on partnership with patients, carers and government agencies in order to improve the quality of research that focuses on patient-centred outcomes that will help to improve both outcomes and quality of life in patients with this devastating condition.
Asunto(s)
Enfermedades Intestinales/terapia , Enfermedad Aguda , Adulto , Enfermedad Crónica , Europa (Continente) , Tracto Gastrointestinal/fisiopatología , Humanos , Hidroxizina , Comunicación Interdisciplinaria , Absorción Intestinal , Enfermedades Intestinales/diagnóstico , Enfermedades Intestinales/fisiopatología , Intestinos/fisiopatología , Terapia Nutricional/métodos , Atención Dirigida al Paciente , Calidad de Vida , Factores de Riesgo , Equilibrio HidroelectrolíticoRESUMEN
We recommend that intestinal failure associated liver disease (IFALD) should be diagnosed by the presence of abnormal liver function tests and/or evidence of radiological and/or histological liver abnormalities occurring in an individual with IF, in the absence of another primary parenchymal liver pathology (e.g. viral or autoimmune hepatitis), other hepatotoxic factors (e.g. alcohol/medication) or biliary obstruction. The presence or absence of sepsis should be noted, along with the duration of PN administration. Abnormal liver histology is not mandatory for a diagnosis of IFALD and the decision to perform a liver biopsy should be made on a case-by-case basis, but should be particularly considered in those with a persistent abnormal conjugated bilirubin in the absence of intra or extra-hepatic cholestasis on radiological imaging and/or persistent or worsening hyperbilirubinaemia despite resolution of any underlying sepsis and/or any clinical or radiological features of chronic liver disease. Nutritional approaches aimed at minimising PN overfeeding and optimising oral/enteral nutrition should be instituted to prevent and/or manage IFALD. We further recommend that the lipid administered is limited to less than 1 g/kg/day, and the prescribed omega-6/omega-3 PUFA ratio is reduced wherever possible. For patients with any evidence of progressive hepatic fibrosis or overt liver failure, combined intestinal and liver transplantation should be considered.
Asunto(s)
Enfermedades Intestinales/complicaciones , Enfermedades Intestinales/terapia , Hepatopatías/complicaciones , Hepatopatías/diagnóstico , Terapia Nutricional/métodos , Adulto , Bilirrubina/sangre , Biopsia , Nutrición Enteral , Europa (Continente) , Humanos , Hiperbilirrubinemia , Enfermedades Intestinales/diagnóstico , Lípidos/administración & dosificación , Hígado/patología , Hepatopatías/terapia , Pruebas de Función Hepática , Nutrición Parenteral , Sepsis/complicaciones , Sociedades MédicasRESUMEN
INTRODUCTION: Antioxidants essential trace elements (TEs), selenium (Se), zinc (Zn) and copper (Cu) are key dietary components and their supplementation in parenteral nutrition (PN) is recommended. However, the frequency of marginal deficiencies and related clinical outcomes remain poorly known in patients receiving long-term PN. METHODS AND OBJECTIVES: We conducted a retrospective observational study whose aim was to determine in a cohort of patients (n = 73) with chronic intestinal failure (CIF) enrolled in a tertiary home PN center and receiving long-term PN with systematic multi-TE supplementation, the prevalence of low serum TEs levels. The goal was also to assess mid-term incidence of serious infection and its associated factors. RESULTS: Among the 73 studied patients, 21.9%, 13.9% and 21.1% had low serum Se (<0.9 µmol/l), Cu (<12.7 µmol/l) and Zn (<12.5 µmol/l) levels, respectively. There was no difference between short bowel syndrome (SBS) and non-SBS patients. 30 patients had at least one of the three serum TEs levels under the cut-off values of deficiency. No specific disease and/or underlying intestinal anatomy were associated with low serum TEs concentration. Cumulative incidence rates of serious infection were 11.1% 95CI[5.7-21.0] and 19.5% 95CI[12.0-30.7] at 6 months and 1 year, respectively. Central venous catheter-related bloodstream infection was the most common infection. Low serum Se was independently associated with a higher risk to develop serious infection (HR 2.65 95CI[1.01-6.97]). CONCLUSION: Low serum TEs concentration is a frequent condition in patients with CIF even with systematic multi-TE supplementations. Se deficiency exposes to a greater risk of serious infection. This suggests that frequent TEs dosage in this population as well as individually tailored supplementation may be beneficial.
Asunto(s)
Antioxidantes/administración & dosificación , Enfermedades Transmisibles/epidemiología , Oligoelementos/administración & dosificación , Adulto , Anciano , Catéteres Venosos Centrales/efectos adversos , Catéteres Venosos Centrales/microbiología , Enfermedades Transmisibles/tratamiento farmacológico , Cobre/administración & dosificación , Cobre/sangre , Cobre/deficiencia , Femenino , Estudios de Seguimiento , Bacterias Gramnegativas , Humanos , Incidencia , Enfermedades Intestinales/sangre , Enfermedades Intestinales/microbiología , Enfermedades Intestinales/terapia , Masculino , Persona de Mediana Edad , Nutrición Parenteral en el Domicilio , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , Selenio/administración & dosificación , Selenio/sangre , Selenio/deficiencia , Síndrome del Intestino Corto/sangre , Síndrome del Intestino Corto/microbiología , Síndrome del Intestino Corto/terapia , Oligoelementos/sangre , Oligoelementos/deficiencia , Zinc/administración & dosificación , Zinc/sangre , Zinc/deficienciaRESUMEN
BACKGROUND: In phase III clinical studies, treatment with teduglutide was associated with clinically meaningful reductions (≥20% from baseline) in parenteral support (PS; parenteral nutrition and/or intravenous fluids) requirements in adult patients with intestinal failure associated with short bowel syndrome (SBS-IF). This analysis reports clinical characteristics of patients who achieved complete independence from PS during teduglutide treatment. MATERIALS AND METHODS: Post hoc analysis of adult patients who achieved complete PS independence during treatment with teduglutide 0.05 mg/kg/d. Data were pooled from 5 teduglutide clinical trials (2 phase III placebo-controlled trials [NCT00081458 and NCT00798967] and their respective extension studies [NCT00172185, NCT00930644, NCT01560403]). Descriptive statistics were used; no between-group comparisons were performed because of the small sample size and lack of comparator. RESULTS: Of 134 patients, 16 gained oral or enteral autonomy after a median of 5 years of PS dependence and 89 weeks of teduglutide treatment. Demographic and baseline disease characteristics varied among patients (median age, 55 years; 50% men; median baseline PS volume, 5.1 L/wk; median residual small intestine length, 52.5 cm). Most patients who achieved PS independence had colon-in-continuity; however, there was no significant difference in the frequency of PS independence among patients who maintained colon-in-continuity vs those who did not. CONCLUSION: Findings from this post hoc analysis suggest that oral or enteral autonomy is possible for some patients with SBS-IF who are treated with teduglutide, regardless of baseline characteristics and despite long-term PS dependence.
Asunto(s)
Fármacos Gastrointestinales/uso terapéutico , Enfermedades Intestinales/terapia , Soluciones para Nutrición Parenteral/administración & dosificación , Nutrición Parenteral , Péptidos/uso terapéutico , Síndrome del Intestino Corto/terapia , Adulto , Determinación de Punto Final , Femenino , Humanos , Intestinos/efectos de los fármacos , Intestinos/fisiopatología , Masculino , Persona de Mediana EdadRESUMEN
Short bowel syndrome (SBS) patients developing hyperphagia have a better outcome. Gastrointestinal endocrine adaptations help to improve intestinal functions and food behaviour. We investigated neuroendocrine adaptations in SBS patients and rat models with jejuno-ileal (IR-JI) or jejuno-colonic (IR-JC) anastomosis with and without parenteral nutrition. Circulating levels of ghrelin, PYY, GLP-1, and GLP-2 were determined in SBS rat models and patients. Levels of mRNA for proglucagon, PYY and for hypothalamic neuropeptides were quantified by qRT-PCR in SBS rat models. Histology and immunostaining for Ki67, GLP-1 and PYY were performed in SBS rats. IR-JC rats, but not IR-JI, exhibited significantly higher crypt depths and number of Ki67-positive cells than sham. Fasting and/or postprandial plasma ghrelin and PYY concentrations were higher, or tend to be higher, in IR-JC rats and SBS-JC patients than in controls. Proglucagon and Pyy mRNA levels were significantly enhanced in IR-JC rats. Levels of mRNA coding hypothalamic orexigenic NPY and AgRP peptides were significantly higher in IR-JC than in sham rats. We demonstrate an increase of plasma ghrelin concentrations, major changes in hypothalamic neuropeptides levels and greater induction of PYY in SBS-JC rats and patients suggesting that jejuno-colonic continuity creates a peculiar environment promoting further gut-brain adaptations.
Asunto(s)
Proteína Relacionada con Agouti/metabolismo , Colon/patología , Ghrelina/sangre , Hipotálamo/metabolismo , Yeyuno/patología , Neuropéptido Y/metabolismo , Síndrome del Intestino Corto/metabolismo , Adulto , Anciano , Anastomosis Quirúrgica , Animales , Modelos Animales de Enfermedad , Conducta Alimentaria , Femenino , Péptido 1 Similar al Glucagón/sangre , Péptido 2 Similar al Glucagón/sangre , Humanos , Hiperfagia/metabolismo , Mucosa Intestinal/metabolismo , Antígeno Ki-67/metabolismo , Masculino , Persona de Mediana Edad , Péptido YY/sangre , Proglucagón/metabolismo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Reacción en Cadena en Tiempo Real de la PolimerasaRESUMEN
OBJECTIVE: To describe drug prescription patterns in patients with short bowel syndrome (SBS). METHODS: The drug prescriptions of patients suffering from SBS type 1 to 3 were compared. RESULTS: Seventy-nine percent of the drugs were prescribed by oral route, and this proportion was significantly higher in patients with type 3 compared to tose with type 1. Twenty-nine percent of prescriptions were dietary supplement-drugs, 14.3% were gastrointestinal drugs and 11.4% were cardiovascular drugs. Oral prescription medications for SBS concerned many drug categories. The number of gastrointestinal or dietary supplement drugs was comparable between the 3 types. Drug doses were not increased compared with the recommendations, except for gastrointestinal drugs. CONCLUSION: The oral administration is common and at usual dosage in patients with SBS despite a lack of studies on absorption that may help to individualize drug prescription.
Asunto(s)
Pautas de la Práctica en Medicina/estadística & datos numéricos , Síndrome del Intestino Corto/fisiopatología , Administración Oral , Fármacos Cardiovasculares/administración & dosificación , Suplementos Dietéticos , Femenino , Fármacos Gastrointestinales/administración & dosificación , Humanos , MasculinoRESUMEN
PRECIS: The aim of this study was to evaluate the safety and tolerance of a soybean/MCT/olive/fish oil emulsion in intestinal failure patients on long-term parenteral nutrition. 73 patients took part in a randomized, double-blind, multi-centre study. The study demonstrates that the lipid emulsion containing four different types of oils is safe and well tolerated in long-term PN. BACKGROUND & AIM: Long-term safety and efficacy of a lipid emulsion containing soybean oil, medium-chain triglycerides (MCT), olive oil and fish oil and enriched in vitamin E have not yet been evaluated in adult patients requiring long-term parenteral nutrition (PN). METHODS: Randomised, controlled, double-blind, multicentre study in 73 patients with stable intestinal failure, requiring PN with either soybean/MCT/olive/fish emulsion (SMOFlipid, n = 34) or soybean emulsion (Intralipid, control n = 39) for 4 weeks. Safety and tolerance were monitored with standard clinical laboratory parameters, adverse events (AEs, according to the Common Terminology Criteria for Adverse Events (CTCAE) classification v 3.0) and vital signs. Fatty acid pattern in red blood cell phospholipids and plasma lipoproteins, serum Vitamin E, Interleukin (IL)-6, and soluble tumour necrosis (s-TNF)-receptor(R)II were also evaluated. RESULTS: Mean concentrations of alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin, whilst remaining within the reference range, were significantly lower with soybean/MCT/olive/fish (SMOF) oil emulsion after the treatment period compared to control. Eicosapentaenoic acid, docosahexaenoic acid and n-3/n-6 fatty acid ratio increased in the SMOF group, while they remained unchanged in the control in plasma and RBC. Serum α-tocopherol concentrations significantly increased in the study group compared to control (p = 0.0004). IL-6 and sTNF-RII levels did not change during the study period. Grade 4 (serious) adverse events occurred in 2 SMOF patients and in 8 control patients (p = 0.03). CONCLUSIONS: Soybean/MCT/olive/fish emulsion was safe and well tolerated over 4 weeks and leads to positive change in fatty acids profile.
Asunto(s)
Emulsiones Grasas Intravenosas/administración & dosificación , Soluciones para Nutrición Parenteral/administración & dosificación , Nutrición Parenteral/efectos adversos , Fosfolípidos/administración & dosificación , Aceite de Soja/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Bilirrubina/sangre , Ácidos Docosahexaenoicos/sangre , Método Doble Ciego , Ácido Eicosapentaenoico/sangre , Emulsiones/administración & dosificación , Ácidos Grasos Omega-6/sangre , Femenino , Aceites de Pescado/administración & dosificación , Humanos , Interleucina-6/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Aceite de Oliva , Aceites de Plantas/administración & dosificación , Receptores del Factor de Necrosis Tumoral/sangre , Triglicéridos/administración & dosificación , Vitamina E/administración & dosificación , Vitamina E/sangre , Adulto JovenRESUMEN
PURPOSE OF REVIEW: To point new insights in the cholestasis that is a complication of both intestinal failure and parenteral nutrition. View on liver disease has recently evolved with the onset of fish oil-based intravenous lipid emulsions (ILE). RECENT FINDINGS: Focused on the role of ILE in causing liver disease. Reversal of cholestasis was recently achieved in infants with short bowel syndrome, by replacing the 'reference' soybean oil-based ILE by fish oil-based ILE. SUMMARY: It is likely that this reversal involves several factors such as the change in n-6: n-3 ratio, the reduction in phytosterol load, the increased provision of alpha-tocopherol as antioxidant agent. Alternative issue might be based on the use of a new generation of ILE aiming to provide n-3 and to reduce n-6 fatty acids load while enhancing alpha-tocopherol intake. New data are based on the use of an ILE containing a balanced proportion of four types of oil as a physical mixture of 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil and 15% fish oil with amounts of alpha-tocopherol calculated according to the number of double bonds. This new emulsion was reported to be beneficial in reversing or preventing liver disease.
Asunto(s)
Colestasis/terapia , Emulsiones Grasas Intravenosas/uso terapéutico , Aceites de Pescado/uso terapéutico , Enfermedades Intestinales/terapia , Hepatopatías/prevención & control , Nutrición Parenteral Total/efectos adversos , Síndrome del Intestino Corto/terapia , Aceite de Soja/uso terapéutico , Colestasis/etiología , Emulsiones Grasas Intravenosas/efectos adversos , Aceites de Pescado/efectos adversos , Humanos , Lactante , Recién Nacido , Enfermedades Intestinales/complicaciones , Hepatopatías/etiología , Trasplante de Hígado , Factores de Riesgo , Síndrome del Intestino Corto/complicaciones , Aceite de Soja/efectos adversosRESUMEN
Management of home parenteral support in adult benign but chronic intestinal failure patients requires a nutrition support team using disease-specific pathways. Education of patients to ensure they self manage home parenteral nutrition (HPN) is cornerstone to obtain minimal rate of technical complications and improvement in quality of life. Nutritive mixtures, compounded by pharmacists in single "all-in-one" bags, must be tailored according to the nutritional and intestinal status of individual patients with definition of macronutrients and water-electrolyte needs, respectively. Each PN cycle should be complete in essential nutrients to be nutritionally efficient and should have sufficient amounts of amino acids, dextrose, water, minerals, and micronutrients to avoid deficiency. When the nutritional goal is achieved, a minimum number of PN cycles per week should be implemented, guided ideally by digestive balance(s) (In-Out) of macronutrients and minerals of individual patients. Indeed, HPN is, in most cases, a complementary nonexclusive mode of nutritional support. In short gut patients--who represent 75% of chronic intestinal failure patients--encouraging enteral feeding decrease PN delivery and the risk of metabolic liver disease associated with HPN. In short gut patients with no severe renal impairment, blood citrulline dosage, in association with the remnant anatomy, is a tool to delineate transient from permanent intestinal failure. The latter group includes candidates for trophic gut factors and rehabilitative or reconstructive surgery, including intestinal transplantation. Thus, outcome improvement for intestinal failure patients needs intestinal failure teams having expertise in all medical and surgical aspects of this field.
Asunto(s)
Síndromes de Malabsorción/terapia , Nutrición Parenteral en el Domicilio , Guías de Práctica Clínica como Asunto , Adulto , Enfermedad Crónica , Humanos , Grupo de Atención al Paciente , Educación del Paciente como AsuntoRESUMEN
Long-term (i.e. home) parenteral nutrition has been advocated to be responsible for several metabolic complications among which hepatic disorders have long been the most relevant in view of patients' prognosis. The increased knowledge of the pathophysiologic factors associated to parenteral nutrition-related liver disease as well as the regular improvement of the components and the techniques used for parenteral nutrition leaded progressively to a better prevention of these side effects. This case report focuses on the potential interest of olive oil-based lipid emulsions in home parenteral nutrition patients, in selected situations of home parenteral nutrition-associated metabolic liver disease.